These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 25162417)
1. A critical role for the mTORC2 pathway in lung fibrosis. Chang W; Wei K; Ho L; Berry GJ; Jacobs SS; Chang CH; Rosen GD PLoS One; 2014; 9(8):e106155. PubMed ID: 25162417 [TBL] [Abstract][Full Text] [Related]
2. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells. Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880 [TBL] [Abstract][Full Text] [Related]
3. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta. Rahimi RA; Andrianifahanana M; Wilkes MC; Edens M; Kottom TJ; Blenis J; Leof EB Cancer Res; 2009 Jan; 69(1):84-93. PubMed ID: 19117990 [TBL] [Abstract][Full Text] [Related]
4. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway. Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477 [TBL] [Abstract][Full Text] [Related]
5. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Gökmen-Polar Y; Liu Y; Toroni RA; Sanders KL; Mehta R; Badve S; Rommel C; Sledge GW Breast Cancer Res Treat; 2012 Dec; 136(3):673-82. PubMed ID: 23085766 [TBL] [Abstract][Full Text] [Related]
6. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms. Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770 [TBL] [Abstract][Full Text] [Related]
7. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700 [TBL] [Abstract][Full Text] [Related]
8. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation. Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732 [TBL] [Abstract][Full Text] [Related]
9. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906 [TBL] [Abstract][Full Text] [Related]
10. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis. Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809 [TBL] [Abstract][Full Text] [Related]
11. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells. Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608 [TBL] [Abstract][Full Text] [Related]
12. Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis. Li J; Ren J; Liu X; Jiang L; He W; Yuan W; Yang J; Dai C Kidney Int; 2015 Sep; 88(3):515-27. PubMed ID: 25970154 [TBL] [Abstract][Full Text] [Related]
13. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820 [TBL] [Abstract][Full Text] [Related]
15. Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma. Mazan-Mamczarz K; Peroutka RJ; Steinhardt JJ; Gidoni M; Zhang Y; Lehrmann E; Landon AL; Dai B; Houng S; Muniandy PA; Efroni S; Becker KG; Gartenhaus RB Cell Commun Signal; 2015 Mar; 13():15. PubMed ID: 25849580 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells. Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS Respir Res; 2014 Feb; 15(1):26. PubMed ID: 24571487 [TBL] [Abstract][Full Text] [Related]
17. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage. Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870 [TBL] [Abstract][Full Text] [Related]